AUXL (Auxilium Pharmace)
All Pro Portfolios with AUXL
- Total Pro Portfolios with AUXL:
- George Soros
- show more
- 1
All Do-It-Yourself Portfolios with AUXL
- Total Do-It-Yourself Portfolios with AUXL:
- BK Portfolio Pros
- paul louie Portfolio 1
- HotCash
- galatica
- SUPRATRADE 0806072111 FOR MONDAY
- Terry 2
- zekehound Portfolio 1
- SUPRATRADE "BUY IT ALL TODAY" 0908071816(09.august)
- cfox498 Portfolio BO
- uniquelydriven1 Portfolio
- Who Would Short Soros Stocks: Short Squeeze Plays
- Ed Mahaffey Portfolio - Blended
- kiwiloz
- show more
- 25
- my tries
- Stephen Whelan Portfolio 1
- tpatton Portfolio 1
- djf Portfolio 1
- Cramer's Take on Select Soros Plays
- Short Squeeze George Soros Stocks
- SUPRATRADE "BUY IT ALL NOW"!!! 0408070122(august 4)
- Trader Doug
- BENITRANS HS-SFM-X
- chaotic Portfolio 1
- zekehound Portfolio 2
- Barron's Summary 8-09-2008
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:kiwiloz |
Date:08 17 08 |
growth |
|
Not yet rated
Rate now:
|
|
By:barrons2 |
Date:08 09 08 |
COUNTING THE POTENTIAL for both Testim and Xiaflex, Lee and PAI partner Joon Yun see Auxilium shares reaching 100 over three years, up from about 37 recently. So far this year, the shares are up about 21%. Auxilium, founded in 1999, has yet to turn a profit. It lost more than $40 million in each of the past two years. But that could soon change. Lee values the Testim business at $1 billion. That assumes the business is worth about five times its expected sales three years from now -- a conservative valuation for a biotech concern. The Xiaflex business, he suggests, is worth about $3 billion. He figures the business can capture 20% of patients with the hand disorder by 2011, winning $300 million in sales. To that sum he applies a multiple of 10, which is not unusual for super-high-growth biotech businesses. |
|
Not yet rated
Rate now:
|
|
By:Dan Jacobs |
Date:01 14 08 |
biotech spec that makes Xiaflex, in pahse 3 trials for Dupuytren's contractures, Peyronie's disease and frozen shoulder. |
|
Not yet rated
Rate now:
|
|
By:Dan Jacobs |
Date:01 14 08 |
biotech spec that makes Xiaflex, in pahse 3 trials for Dupuytren's contractures, Peyronie's disease and frozen shoulder. |
|
Not yet rated
Rate now:
|
|
Date:01 08 08 |
|
11.6 |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Auxilium Pharma (AUXL) was downgraded to Neutral, Merrill Lynch said. Valuation call, as the stock is already pricing in 100% clinical success for Xiaflex. |
|
Not yet rated
Rate now:
|
|
By:supratrade |
Date:08 09 07 |
BUY |
|
Not yet rated
Rate now:
|
|
By:supratrade |
Date:08 03 07 |
BUY |
|
Not yet rated
Rate now:
|
|
By:stockerblog |
Date:07 22 07 |
12.2 17.38% |
|
Not yet rated
Rate now:
|
|
By:tshot98 |
Date:07 05 07 |
long term payoff |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |